AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23038750
Drug: Polypill strategy
RxNorm normalized name: POLYPILUS FRONDOSUS WHOLE
DrugBank: Grifola frondosa whole (DB19262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill strategy (combining aspirin, a statin, and two blood pressure lowering agents)
Trial: 20137476
Drug: Low-dose amiodarone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amiodarone (10 mg/kg daily for 7 days before surgery and 200 mg daily for 10 days postoperatively)
Trial: 9833596
Drug: Racemic propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic propafenone (150 mg every 6 h)
Trial: 9833596
Drug: (S)‐propafenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (S)‐propafenone (150 mg every 6 h)
Trial: 9833596
Drug: (R)‐propafenone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)‐propafenone (150 mg every 6 h)
Trial: 8589464
Drug: Patient age,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient age, use of calcium channel blockers, presence of diabetes mellitus (DM)
Trial: 2666363
Drug: Initial local
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial local control with radiation therapy or radiation plus surgery
Trial: 2666363
Drug: Salvage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvage therapy for metastatic disease
Trial: 793437
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon (HLI) 3 X 10(‐6) units/ml, two drops twice daily
Trial: 30700356
Drug: Trastuzumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab with neoadjuvant chemotherapy (n=89, n=64 received complete standard dose)
Trial: 30700356
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy only (Control group, n=67)
Trial: 19176440
Drug: N-terminal BNP-guided
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-terminal BNP-guided therapy
Trial: 12754730
Drug: Psychotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotic group nurses (read vignette with patient on haloperidol, benztropine, lorazepam, trazadone, fluoxetine, and lithium)
Trial: 12754730
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group nurses (read vignette without psychiatric medication)
Trial: 9369825
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline sulfate (0.25 mg)
Trial: 24773760
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MIG) plus standard care (information sheet on glaucoma and its treatment)
Trial: 22466942
Drug: Auricular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular therapy combined with optimized Yinxieling Formula
Trial: 15951736
Drug: PTNS performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTNS performed weekly (Group A)
Trial: 10600247
Drug: Alcohol (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (single dose)
Trial: 2220647
Drug: Nonpharmacologic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic therapy combined with one of five active drug regimens (acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril)
Trial: 2220647
Drug: Nonpharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatment only
Trial: 93353
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (1.0 up to 1.5 g/day)
Trial: 93353
Drug: Metizol (thiamazol)
RxNorm normalized name: amitriptyline hydrochloride Extended Release Oral Capsule [Lentizol]
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metizol (thiamazol) 60 mg/day
Trial: 93353
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with lithium and metizol
Trial: 23241439
Drug: Drug Free
RxNorm normalized name: Tenscare Pain Aide Drug Free Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Free Interval Strategy (DFIS)
Trial: 17377504
Drug: Tacrolimus (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.05 mg/kg/day)
Trial: 9841603
Drug: Proton‐pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton‐pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium
Trial: 351716
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel administered extraamniotically
Trial: 351716
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (i.v. oxytocin, 20% NaCl solution, Premarin, balloon catheter, Rivanol)
Trial: 30264293
Drug: E6201, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6201, an intravenous MEK1 inhibitor
Trial: 28603112
Drug: Safoof akseer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safoof akseer e jigar (test drug)
Trial: 28603112
Drug: Interferon Alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon Alpha (control therapy)
Trial: 25524478
Drug: Cetuximab with
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab with PX-866 (8 mg p.o. daily)
Trial: 21220064
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for PTSD treatment
Trial: 19736332
Drug: Antipyretic agents
RxNorm normalized name: ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipyretic agents (rectal diclofenac followed by oral ibuprofen or acetaminophen)
Trial: 17577104
Drug: Azelnidipine 8
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8 to 16 mg (average 14.5 mg)
Trial: 17577104
Drug: Amlodipine 2.5
RxNorm normalized name: amlodipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 2.5 to 7.5 mg (average 4.9 mg)
Trial: 9115054
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment initiation
Trial: 9115054
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment discontinuation
Trial: 3086023
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition with hypertonic glucose at energy intakes of 6650 to 17,100 kJ/day
Trial: 3086023
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition with hypertonic glucose
Trial: 19695405
Drug: Generic enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic enoxaparin 60 mg SC
Trial: 19695405
Drug: Branded enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded enoxaparin 60 mg SC
Trial: 16897979
Drug: S‐1 +
RxNorm normalized name: Tegafur/Gimeracil/Oteracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐1 + biweekly docetaxel (DOC) combination therapy
Trial: 10757544
Drug: High-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat diet (39.5% calories as fat) with red wine (240 mL/d) for 30 days
Trial: 10757544
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (27% calories as fat) with red wine (240 mL/d) for 30 days
Trial: 1633702
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin (CS) formulation (10%)
Trial: 1633702
Drug: Flumethasone pivalate
RxNorm normalized name: Flumethasone Pivalate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumethasone pivalate (FP) formulation (0.02%)
Trial: 26840505
Drug: Xanthohumol drink
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthohumol drink (12 mg XN/P/day)
Trial: 24751788
Drug: Clonidine 1
RxNorm normalized name: apraclonidine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 1 μg/kg/hr
Trial: 22952182
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (600 μg retinyl palmitate/d)
Trial: 22952182
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A (300 μg retinyl palmitate/d)
Trial: 22952182
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A + zinc (10 or 20 mg zinc sulfate/d)
Trial: 17285405
Drug: Intravenous-based (IV)
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous-based (IV) anesthesia with modified neurolept anesthesia (droperidol 0.2 mg/kg and pentazocine 0.15-0.3 mg/kg) and postoperative intravenous infusion of buprenorphine (20 µg/ml) via PCA pump.
Trial: 17285405
Drug: Epidural-based (EPI)
RxNorm normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural-based (EPI) anesthesia with combined epidural analgesia and general anesthesia (sevoflurane and nitrous oxide) followed by epidural infusion of 0.125% bupivacaine and 5 µg/ml buprenorphine.
Trial: 11851643
Drug: L-N(G)-monomethyl arginine
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-N(G)-monomethyl arginine (LNMMA) at doses of 0.1, 0.3, 1.0 and 3.0 mg kg‐1 min‐1
Trial: 30921490
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex, 100 mg/mL)
Trial: 30921490
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of CBD
Trial: 16933434
Drug: Conjoint group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint group treatment
Trial: 16933434
Drug: Gender-specific group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-specific group treatment
Trial: 11402826
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide eye drops, 3 times daily for a mean follow up of 9 months
Trial: 9364107
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (N=15)
Trial: 4035650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AT III and Heparin
Trial: 24643901
Drug: Heliox-driven bronchodilation
RxNorm normalized name: Helixate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heliox-driven bronchodilation therapy
Trial: 24643901
Drug: Air-driven bronchodilation
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-driven bronchodilation therapy
Trial: 18808627
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group, n = 23)
Trial: 16160598
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg orally twice daily on the day before and the day of contrast administration)
Trial: 16160598
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acetylcysteine, saline 0.9% intravenously at 1 mL/kg/h for 12 hours before and after contrast administration)
Trial: 16160598
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine >2.5 mg/dL
Trial: 16160598
Drug: Baseline serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline serum creatinine <2.5 mg/dL
Trial: 9919322
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with Nortriptyline (NT)
Trial: 9919322
Drug: Maintenance monthly
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance monthly IPT (combined with NT or placebo)
Trial: 8787856
Drug: Temporary high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary high-dose rate 125I implant
Trial: 8787856
Drug: Permanent low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Permanent low-dose rate 125I implant
Trial: 30857609
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 4 mg with ropivacaine 0.75% (3 ml) and saline (1 ml)
Trial: 30857609
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 4 mg with perineural saline (1 ml)
Trial: 30857609
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with perineural saline (1 ml) and intravenous saline (1 ml)
Trial: 19475410
Drug: NaP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaP + laxative
Trial: 17373902
Drug: Targeted or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted or biological therapies
Trial: 17373902
Drug: Newer chemotherapeutic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer chemotherapeutic agents
Trial: 14729785
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid (UA) administration
Trial: 26711384
Drug: Limited margins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited margins IMRT with temozolomide chemotherapy
Trial: 26711384
Drug: Routine margins
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine margins IMRT with temozolomide chemotherapy
Trial: 23275036
Drug: Acetazolamide (AZ)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (AZ) 1,000 mg intravenous administration (single dose)
Trial: 20644497
Drug: Lactobacillus crispatus
RxNorm normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus crispatus CTV‐05 (LACTIN‐V) administered by a vaginal applicator at 2 × 10 colony‐forming units (cfu)/dose for 5 days followed by weekly application for 2 weeks
Trial: 8690121
Drug: GH +
RxNorm normalized name: Delsym Cough + Cold Daytime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH + hCG protocol: 4 IU SC GH daily 8 days before and throughout the hCG phase
Trial: 6791938
Drug: Indomethacin treatment
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin treatment (25 mg x 4 daily)
Trial: 31725142
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery
Trial: 26340264
Drug: DHA plus
RxNorm normalized name: PNV-DHA Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA plus EPA (2 g/day)
Trial: 23657962
Drug: Olmesartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan + Amlodipine (fixed combination)
Trial: 23657962
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of Olmesartan + Amlodipine
Trial: 23657962
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of Olmesartan + Amlodipine
Trial: 11256536
Drug: ACE-inhibitor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor therapy
Trial: 8988997
Drug: Cocaine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.50 mg/kg
Trial: 3326689
Drug: Bay‐o‐1248 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bay‐o‐1248 (20 mg or 10 mg)
Trial: 20423998
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice daily p.o. for a minimum of 14 days)
Trial: 20423998
Drug: Control (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (not receiving a Cox inhibitor)
Trial: 15370247
Drug: Chlorambucil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil 0.1 mg/kg/day indefinitely
Trial: 15370247
Drug: Chlorambucil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil 0.1 mg/kg/day plus theophylline 200 mg bid, orally
Trial: 24322182
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g/vitamin D₃ 1000 IU daily
Trial: 21939611
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (olanzapine, risperidone, quetiapine)
Trial: 20137765
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IG, Lantus)
Trial: 20137765
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (ID, Levemir)
Trial: 20137765
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (ID)
Trial: 16029567
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg/kg intravenous injection
Trial: 28860128
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 μg/kg/min)
Trial: 26817183
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A split injection sites
Trial: 26817183
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A non-split injection sites
Trial: 9106936
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg anti-TNF-alpha moab
Trial: 9106936
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg anti-TNF-alpha moab
Trial: 19216705
Drug: Bepotastine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine 10 mg OD tablet
Trial: 11583747
Drug: Invasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive therapy (revascularisation)
Trial: 3284400
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (F-TTS) 75 micrograms/h
Trial: 3284400
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (F-TTS)
Trial: 3284400
Drug: Fentanyl transdermal
RxNorm normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl transdermal patches (F-TTS) and Placebo
Trial: 31343521
Drug: HIIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIT performed thrice weekly (HIIT×3/wk)
Trial: 31343521
Drug: HIIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIT performed twice weekly (HIIT×2/wk)
Trial: 31343521
Drug: HIIT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIT performed once weekly (HIIT×1/wk)
Trial: 31343521
Drug: MICT performed
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MICT performed thrice weekly (MICT×3/wk)